SALIAI

What SALIAI does

SALIAI is a Guangzhou-headquartered Chinese biotechnology company founded in 2009 and listed on China's National Equities Exchange and Quotations (NEEQ) under stock code 831049. The company develops stem cell and regenerative medicine solutions, anchored by a proprietary patented cellular essence technology platform. SALIAI has built a substantial intellectual property base, reporting over 300 authorized patents, five National Patent Excellence Awards, and a National Enterprise Technology Center designation from the Chinese government. The company employs between 501 and 1,000 people.

The company's recent strategic posture centers on international expansion, including the establishment of a Stem Cell Innovation Association in the Guangdong-Hong Kong-Macao Greater Bay Area and concurrent implementation of digital systems across the organization. In February 2026, SALIAI was recognized by Shangpu Group as a 'Global Pioneer in Patented Cellular Essence' following a global market study. Despite this positioning, the input data does not disclose specific named products, pricing models, customer segments, or go-to-market mechanics, leaving the commercial revenue model opaque.

Financial data covering 2019-2023 shows a steep deterioration: revenue contracted from approximately 25.9B in 2019 to 13.4B in 2023 (units ambiguous in source), while EBITDA moved from positive 2.9B to negative 5.3B and net income from positive 1.5B to negative 9.0B. This combination of shrinking top-line, deepening losses, and limited disclosed commercial detail frames SALIAI as a patent-rich biotech under significant operational and financial stress.

Name

SALIAI

Legal name

Saliai

Website

https://saliai.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

501–1,000 employees

Short description

SALIAI is a Guangzhou-based Chinese biotechnology company, founded in 2009 and NEEQ-listed, that develops stem cell and regenerative medicine solutions built on patented cellular essence technology. It serves the biotech sector with a 300+ patent portfolio while pursuing international expansion amid declining financial performance.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Stem cell research
• Regenerative medicine
• Cellular essence technology
• Biotechnology solutions
• Stem cell applications

Headquarters

HQ city

Guangzhou

HQ country

China

HQ region

Asia

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Core offering

SALIAI develops stem cell and regenerative medicine solutions built on its patented Cellular Essence technology. The company conducts stem cell research and translates it into commercial applications for the biotechnology sector, supported by a portfolio of more than 300 authorized patents. It is also implementing digital systems and expanding internationally via a Stem Cell Innovation Association in the Guangdong-Hong Kong-Macao Greater Bay Area.

Product overview

SALIAI is a biotechnology company engaged in stem cell research and commercial applications. The company reports over 300 authorized patents and holds five National Patent Excellence Awards along with a National Enterprise Technology Center designation. SALIAI is expanding internationally while implementing digital systems and has established a Stem Cell Innovation Association in the Guangdong-Hong Kong-Macao Greater Bay Area. No specific named products, modules, or detailed product portfolio information is available in the provided sources.

Differentiator

Problem solved

Functional benefit

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Stem Cell Innovation AssociationcoreStrategic or Co-development PartnerSALIAI is establishing a Stem Cell Innovation Association in the Guangdong-Hong Kong-Macao Greater Bay Area as part of its international expansion and digital systems implementation strategy.

Scale indicators2 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Mesoblast: Mesoblast develops mesenchymal stem cell (MSC) therapies for inflammatory conditions and is one of the most directly comparable allogeneic stem cell therapy developers globally. SALIAI's focus on cellular essence and stem cell commercialization mirrors Mesoblast's strategy of translating MSC biology into commercial therapeutics.
• Vericel Corporation: Vericel commercializes autologous cell therapies including MACI (cartilage repair) and Epicel (burn treatment), offering a directly comparable model of a stem cell-derived therapy company that has successfully reached commercial revenue.
• Pluri (formerly Pluristem Therapeutics): Pluri develops placenta-derived cell therapies with proprietary 3D manufacturing technology. Comparable to SALIAI as a stem cell platform company focused on proprietary cellular expansion and commercialization rather than single-product development.
• Athersys: Athersys develops MultiStem, an allogeneic stem cell therapy for stroke, ARDS, and inflammatory conditions. Comparable to SALIAI as an allogeneic stem cell platform developer targeting multiple therapeutic indications.
• Capricor Therapeutics: Capricor develops cell therapies including CAP-1002 (cardiac-derived cells) for Duchenne muscular dystrophy and other indications. Comparable to SALIAI as a stem cell-derived therapeutic company pursuing commercialization across multiple indications.
• BrainStorm Cell Therapeutics: BrainStorm develops autologous MSC-based cell therapies, primarily for neurodegenerative diseases. Comparable to SALIAI as a clinical-stage company commercializing proprietary stem cell platforms.
• Cellular Biomedicine Group: Cellular Biomedicine Group is a China-based cell therapy developer focused on autologous and allogeneic cell therapies for cancer and orthopedic indications. It is the closest geographic and therapeutic peer to SALIAI among publicly traded cell therapy companies.

Regional players

• China Regenerative Medicine International: China Regenerative Medicine International is a Hong Kong-listed stem cell and regenerative medicine company focused on the Greater China market. Directly comparable to SALIAI as a regional stem cell commercialization peer operating in adjacent China-Hong Kong geography.

Emerging players

• Cynata Therapeutics: Cynata develops Cymerus, a MSC platform using iPSC-derived mesenchymal stem cells. Comparable to SALIAI's stem cell platform approach, with Cynata being a smaller, more narrowly focused emerging peer.
• Holostem Terapie Avanzate: Holostem develops epithelial stem cell-based advanced therapies for severe ocular burns and other rare conditions. Comparable to SALIAI as a niche stem cell platform developer with EU regulatory-approved products.

Market position

Strengths4 records

Weaknesses3 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SALIAI